ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
…, S Daneshmand, S Sharma, BG Zimmermann, H Sethi… - Nature, 2021 - nature.com
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …
Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer
Importance Novel sensitive methods for detection and monitoring of residual disease can
improve postoperative risk stratification with implications for patient selection for adjuvant …
improve postoperative risk stratification with implications for patient selection for adjuvant …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
…, M Louie, P Billings, B Zimmermann, H Sethi… - Nature Cancer, 2020 - nature.com
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with cancer.
However, existing biomarkers do not reliably predict treatment response across diverse …
However, existing biomarkers do not reliably predict treatment response across diverse …
Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder …
…, K Birkenkamp-Demtröder, H Sethi… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Novel sensitive methods for early detection of relapse and for monitoring therapeutic
efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome …
efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome …
Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence
…, L Kenny, J Stebbing, M Rutherford, H Sethi… - Clinical Cancer …, 2019 - AACR
Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There
are no sensitive and reliable tests to monitor these patients and detect distant metastases …
are no sensitive and reliable tests to monitor these patients and detect distant metastases …
Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior …
…, LH Iversen, KA Gotschalck, H Sethi… - Clinical Cancer …, 2022 - AACR
Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …
relapse detection may have a major impact on treatment decisions and patient management …
[PDF][PDF] Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
…, S Ramesh, R Vyasamneni, B Karki, TE Sciuto, H Sethi… - Cancer Cell, 2022 - cell.com
Neoantigens arising from mutations in tumor DNA provide targets for immune-based therapy.
Here, we report the clinical and immune data from a Phase Ib clinical trial of a personalized …
Here, we report the clinical and immune data from a Phase Ib clinical trial of a personalized …
[HTML][HTML] A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (gBRCA1/2)-mutant
advanced breast cancer, but its activity beyond gBRCA1/2 is poorly understood. We …
advanced breast cancer, but its activity beyond gBRCA1/2 is poorly understood. We …
Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases
…, A Koyen Malashevich, M Malhotra, H Sethi… - JCO Precision …, 2021 - ascopubs.org
PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic colorectal
cancer [mCRC]) relapse postresection. The efficacy of postoperative systemic treatment is …
cancer [mCRC]) relapse postresection. The efficacy of postoperative systemic treatment is …
[PDF][PDF] Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in the …
via non-invasive tumor burden assessment. To investigate subtype-specific differences in the …